Drug–Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein

被引：0
|
作者：
Akihiro Ando
Shinichiro Sasago
Yoshihiro Ohzone
Yohei Miyamoto
机构：
[1] Toray Industries,Pharmaceutical Clinical Research Department
[2] Inc.,Department of Bio Research
[3] Kamakura Techno-Science,ADME & Tox. Research Institute
[4] Inc.,undefined
[5] Sekisui Medical Co.,undefined
[6] Ltd.,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2016年 / 41卷
关键词：
Digoxin; Verapamil; Sodium Dihydrogen Phosphate; Organic Modifier Content; Uremic Pruritus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：549 / 558
页数：9
相关论文
共 50 条
  • [1] Drug-Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein
    Ando, Akihiro
    Sasago, Shinichiro
    Ohzone, Yoshihiro
    Miyamoto, Yohei
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (05) : 549 - 558
  • [2] Psychotropic Drug–Drug Interactions Involving P-Glycoprotein
    Yumiko Akamine
    Norio Yasui-Furukori
    Ichiro Ieiri
    Tsukasa Uno
    CNS Drugs, 2012, 26 : 959 - 973
  • [3] Psychotropic Drug-Drug Interactions Involving P-Glycoprotein
    Akamine, Yumiko
    Yasui-Furukori, Norio
    Ieiri, Ichiro
    Uno, Tsukasa
    CNS DRUGS, 2012, 26 (11) : 959 - 973
  • [4] Evaluation of drug interactions with P-glycoprotein in drug discovery:: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein
    Hochman, JH
    Yamazaki, M
    Ohe, T
    Lin, JH
    CURRENT DRUG METABOLISM, 2002, 3 (03) : 257 - 273
  • [5] Study Models of Drug-Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels
    Veiga-Matos, Jessica
    Morales, Ana I.
    Prieto, Marta
    Remiao, Fernando
    Silva, Renata
    MOLECULES, 2023, 28 (22):
  • [6] P-glycoprotein, a source of drug interactions
    Roussin, Fanny
    Picard, Nicolas
    ACTUALITES PHARMACEUTIQUES, 2020, 59 (601): : 48 - 52
  • [7] The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
    Yu, DK
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (12): : 1203 - 1211
  • [8] Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions
    Marie Lund
    Tonny Studsgaard Petersen
    Kim Peder Dalhoff
    Drugs, 2017, 77 : 859 - 883
  • [9] CLINICAL SIGNIFICANT P-GLYCOPROTEIN DRUG INTERACTIONS?
    Lee, Caroline A.
    Fenner, Katherine S.
    Kempshall, Sarah
    Cook, Jack
    Ware, Joseph Alan
    Troutman, Matthew D.
    DRUG METABOLISM REVIEWS, 2008, 40 : 208 - 208
  • [10] Computer Evaluation of Drug Interactions with P-Glycoprotein
    Lagunin, A. A.
    Gloriozova, T. A.
    Dmitriev, A. V.
    Volgina, N. E.
    Poroikov, V. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2013, 154 (04) : 521 - 524
12345